

Curriculum Vitae

Name : JinMo Yang, M.D., PhD

Affiliation : Professor, Hepatology, St. Vincent's Hospital, The Catholic University of Korea

Date of Birth : Sep 22, 1958

Place of Birth : Taejeon, Korea

Permanent Address : 335-8 Samsung-dong Daejeon-si Korea

Present Address : #1601 Hyundai Lakeville. Songpa-dong, Songpa-gu, Seoul, Korea

Phone : 82-2-578-6474, 82-10-8638-6474

Work Place : Hepato-gastroenterology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea

Address : #93-6, Ji-dong, Paldal-gu 442-723, Suwon, Korea

Phone : 82-31-249-7123

Fax : 82-31-253-8898

Education Career

1976-1983 College of Medicine, The Catholic University of Korea

1989-1992 Postgraduate School, College of Medicine, The Catholic University of Korea(B.S)

1992-1995 Postgraduate School, College of Medicine, The Catholic University of Korea(Ph.D)

Training & Working Career

Training

1986-1990 Intern # Resident of Medicine, St. Mary's Hospital, The Catholic Univ. of Korea

1990-1992 Dept. of Medicine, St. Mary's Hospital, The Catholic Univ. of Korea

1992-2001 Dept. of Medicine, St. Paul's Hospital, The Catholic Univ. of Korea

2001-Present Dept. of Medicine, St. Vincent's Hospital, The Catholic Univ. of Korea

Visiting Scientist

1996.4-1997.12 North Carolina University at Chapel Hill, Pharmacology, Alcoholic liver injury

Academic

1992-1994 Instructor, Dept. of Medicine, The Catholic Univ. of Korea

1994-1997 Assistant Professor, Dept. of Medicine, The Catholic Univ. of Korea

1997-2003 Associate Professor, Dept. of Medicine, The Catholic Univ. of Korea

2003-Present Professor, Dept. of Medicine, The Catholic Univ. of Korea

Medical Society

1990–Present Member, Korean Society of Gastroenterology

1992–Present Member, Korean association study of liver (KASL)

2001–2007 Editor, The Korean Journal of Hepatology

2008–2009 Secretary General of KASL

2018–2019 President of KASL

Clinical Trial Experience

1. Megesterol Treatment in Advanced Hepatocellular Carcinoma, 2002, Singapore
2. Lamivudine durability study (multicenter trial)
3. Clevudine in CHB (Phase III, multicenter trial)
4. Entecavir in CHB